Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06062745 · ClinicalTrials.gov registry record · Phase 1
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
A Phase 1 study of Metastatic Prostate Cancer and Advanced Prostate Cancer, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT06062745: Recruiting Phase 1 study of Metastatic Prostate Cancer and Advanced Prostate Cancer, sponsored by Brigham and Women's Hospital.
NCT06062745 is a Phase 1 study of Metastatic Prostate Cancer and Advanced Prostate Cancer that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 30 participants, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06062745, a Phase 1 study of Metastatic Prostate Cancer and Advanced Prostate Cancer, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA) expression or has neuroendocrine features. The name of the study interventions are: * 18F-fluciclovine-PET/CT scan * Two research blood collections
Primary Outcome
Number of 18F-fluciclovine positive lesions in PSMA-positive tumors on PET Number of fluciclovine positive tumors that are PSMA-negative
Conditions Studied
Interventions
- DRUG 18F-fluciclovine
- DEVICE PET/CT
Study Locations (2)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Brigham and Womens Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 1 |
What NCT06062745 shows while recruiting
NCT06062745 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (84% lower).
The record links to 3 conditions, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which 18F-fluciclovine is the first listed.
NCT06062745 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06062745 about?
NCT06062745 is a clinical study titled "Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT". This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA) expression or has neuroendocrine features....
What is the current status of trial NCT06062745?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-02-01. Estimated completion is 2028-09-01.
What conditions does trial NCT06062745 study?
This clinical trial studies the following conditions: Metastatic Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma.
What interventions are being tested in trial NCT06062745?
The interventions under investigation include: 18F-fluciclovine (DRUG), PET/CT (DEVICE).
Who is sponsoring clinical trial NCT06062745?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06062745 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06062745's enrollment target sits among peer trials
30 31st of 41 higher than 10 of 41 other Metastatic Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of AZD0754 in Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
RECRUITING · Phase 1
-
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
RECRUITING · Phase 1
-
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI